Unknown

Dataset Information

0

RV144 HIV-1 vaccination impacts post-infection antibody responses.


ABSTRACT: The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine efficacy was associated with stronger binding antibody responses to the HIV Envelope (Env) V1V2 region, with decreased efficacy as responses wane. High levels of Ab-dependent cellular cytotoxicity (ADCC) together with low plasma levels of Env-specific IgA also correlated with decreased infection risk. We investigated whether B cell priming from RV144 vaccination impacted functional antibody responses to HIV-1 following infection. Antibody responses were assessed in 37 vaccine and 63 placebo recipients at 6, 12, and 36 months following HIV diagnosis. The magnitude, specificity, dynamics, subclass recognition and distribution of the binding antibody response following infection were different in RV144 vaccine recipients compared to placebo recipients. Vaccine recipients demonstrated increased IgG1 binding specifically to V1V2, as well as increased IgG2 and IgG4 but decreased IgG3 to HIV-1 Env. No difference in IgA binding to HIV-1 Env was detected between the vaccine and placebo recipients following infection. RV144 vaccination limited the development of broadly neutralizing antibodies post-infection, but enhanced Fc-mediated effector functions indicating B cell priming by RV144 vaccination impacted downstream antibody function. However, these functional responses were not associated with clinical markers of disease progression. These data reveal that RV144 vaccination primed B cells towards specific binding and functional antibody responses following HIV-1 infection.

SUBMITTER: Mdluli T 

PROVIDER: S-EPMC7748270 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

RV144 HIV-1 vaccination impacts post-infection antibody responses.

Mdluli Thembi T   Jian Ningbo N   Slike Bonnie B   Paquin-Proulx Dominic D   Donofrio Gina G   Alrubayyi Aljawharah A   Gift Syna S   Grande Rebecca R   Bryson Mary M   Lee Anna A   Dussupt Vincent V   Mendez-Riveria Letzibeth L   Sanders-Buell Eric E   Chenine Agnès-Laurence AL   Tran Ursula U   Li Yifan Y   Brown Eric E   Edlefsen Paul T PT   O'Connell Robert R   Gilbert Peter P   Nitayaphan Sorachai S   Pitisuttihum Punnee P   Rerks-Ngarm Supachai S   Robb Merlin L ML   Gramzinski Robert R   Alter Galit G   Tovanabutra Sodsai S   Georgiev Ivelin S IS   Ackerman Margaret E ME   Polonis Victoria R VR   Vasan Sandhya S   Michael Nelson L NL   Kim Jerome H JH   Eller Michael A MA   Krebs Shelly J SJ   Rolland Morgane M  

PLoS pathogens 20201208 12


The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine efficacy was associated with stronger binding antibody responses to the HIV Envelope (Env) V1V2 region, with decreased efficacy as responses wane. High levels of Ab-dependent cellular cytotoxicity (ADCC) together with low plasma levels of Env-specific IgA also correlated with decreased infection risk. We investigated whether B cell priming from RV144 vaccination impacted functional antibody responses  ...[more]

Similar Datasets

| S-EPMC5439458 | biostudies-literature
| S-EPMC9388370 | biostudies-literature
2019-02-15 | GSE103733 | GEO
| S-EPMC2981674 | biostudies-literature
| S-EPMC4344337 | biostudies-literature
| S-EPMC8438874 | biostudies-literature
| S-EPMC9513331 | biostudies-literature
| S-EPMC6863043 | biostudies-literature
| S-EPMC7406303 | biostudies-literature
| S-EPMC3089979 | biostudies-literature